Stock Alert for ADVENTRX Pharmaceuticals Inc. Issued by Beacon Equity
April 01 2010 - 6:50AM
BeaconEquity.com announces an investment report featuring ADVENTRX
Pharmaceuticals Inc. (AMEX:ANX). The report includes financial,
comparative and investment analyses, and pertinent industry
information you need to know to make an educated investment
decision.
The full report is available at:
http://www.beaconequity.com/i/ANX
Get our alerts BEFORE the rest of the market. Follow us on
Twitter: http://twitter.com/BeaconEquity
ADVENTRX Pharmaceuticals Inc. (ANX) is a development-stage
biopharmaceutical company. The Company's business is focused on
in-licensing, developing and commercializing product candidates for
the treatment of cancer. Its lead product candidates, ANX-530 and
ANX-514, are emulsion formulations of marketed chemotherapy drugs.
ANX is focused primarily on evaluating strategic options, including
the sale or exclusive license of one or more of its product
candidate programs, a strategic business merger and other similar
transactions. In October 2008, ANX announced that it had
discontinued active work on all product candidates other than
ANX-530 and ANX-514. Its wholly owned subsidiaries include SD
Pharmaceuticals Inc. (SDP) and ANX (Europe) Ltd.
Message Board Search for
ANX: http://www.boardcentral.com/boards/ANX
In the report, the analyst notes:
"ANX's net loss applicable to common stock for the fourth
quarter of 2009 was $6.5 million, or $0.04 per share, compared to a
net loss applicable to common stock of $7.5 million, or $0.08 per
share, for the same period in 2008. Included in the net loss
applicable to common stock for the fourth quarter of 2009 was a
non-cash deemed dividend expense of $3.3 million incurred in
connection with the Company's October 2009 equity financing.
"ANX recently announced that it will meet the U.S. Food and Drug
Administration (FDA) in Washington D.C. during the last week of
April 2010 to review the Company's New Drug Application (NDA) for
ANX-530 (vinorelbine injectable emulsion) and the FDA's
refusal-to-file letter. ANX had requested a face-to-face meeting
with the FDA to understand its requirements and define the path to
a successful filing of an ANX-530 NDA at the earliest possible
time."
To read the entire report visit:
http://www.beaconequity.com/i/ANX
See what investors are saying about ANX at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap
report providers. Beacon strives to provide a balanced view of many
promising small-cap companies that would otherwise fall under the
radar of the typical Wall Street investor. We provide investors
with an excellent first step in their research and due diligence by
providing daily trading ideas, and consolidating the public
information available on them. For more information on Beacon
Research, please visit http://www.BeaconEquity.com.
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON
THIS REPORT. We are not registered as a securities broker-dealer or
an investment adviser either with the U.S. Securities and Exchange
Commission (the "SEC") or with any state securities regulatory
authority. We are neither licensed nor qualified to provide
investment advice. Beacon Equity Research nor its affiliates have a
beneficial interest in the mentioned company; nor have they
received compensation of any kind for any of the companies listed
in this communication. The information contained in our report is
not an offer to buy or sell securities. We distribute
opinions, comments and information free of charge exclusively to
individuals who wish to receive them.
CONTACT: Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com
Adventrx (AMEX:ANX)
Historical Stock Chart
From May 2024 to Jun 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2023 to Jun 2024